Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance

Clinicians have very limited options to treat triple-negative breast cancer (TNBC) due to the lack of effective targeted drugs. Recently, the findings of the mechanism underlying tumor-intrinsic immune escape have fueled a wave of studies into immunotherapy in breast cancer (BC). Compared with other...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xupeng Bai, Jie Ni, Julia Beretov, Peter Graham, Yong Li
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Triple-negative breast cancer Microenvironment Immunotherapy Immunotherapeutic resistance Immune checkpoint Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/b70b5e3637074d7693e3d1e8c38ef8fc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b70b5e3637074d7693e3d1e8c38ef8fc
record_format	dspace
spelling	oai:doaj.org-article:b70b5e3637074d7693e3d1e8c38ef8fc2021-12-01T05:06:45ZImmunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance2667-005410.1016/j.jncc.2021.06.001https://doaj.org/article/b70b5e3637074d7693e3d1e8c38ef8fc2021-09-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2667005421000296https://doaj.org/toc/2667-0054Clinicians have very limited options to treat triple-negative breast cancer (TNBC) due to the lack of effective targeted drugs. Recently, the findings of the mechanism underlying tumor-intrinsic immune escape have fueled a wave of studies into immunotherapy in breast cancer (BC). Compared with other BC subtypes, TNBC shows a better response to immunotherapy due to the higher level of tumor mutation burden and lymphocyte infiltration. Thereinto, immune checkpoint inhibitors (ICIs) achieved the first success of immunotherapy for TNBC and are widely utilized with conventional treatments in the neoadjuvant/adjuvant and advanced stages. However, a large number of TNBC patients fail to demonstrate a good response to ICIs, and the acquired resistance to ICI-based therapies is clinically emerging, which is a major challenge for immunotherapy in TNBC. Here we review the latest advances in TNBC immune microenvironment, immunotherapy, and immunotherapeutic resistance and discuss the challenges and potential approaches to improve the clinical benefit of immunotherapy against TNBC.Xupeng BaiJie NiJulia BeretovPeter GrahamYong LiElsevierarticleTriple-negative breast cancerMicroenvironmentImmunotherapyImmunotherapeutic resistanceImmune checkpointNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal of the National Cancer Center, Vol 1, Iss 3, Pp 75-87 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Triple-negative breast cancer Microenvironment Immunotherapy Immunotherapeutic resistance Immune checkpoint Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Triple-negative breast cancer Microenvironment Immunotherapy Immunotherapeutic resistance Immune checkpoint Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Xupeng Bai Jie Ni Julia Beretov Peter Graham Yong Li Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
description	Clinicians have very limited options to treat triple-negative breast cancer (TNBC) due to the lack of effective targeted drugs. Recently, the findings of the mechanism underlying tumor-intrinsic immune escape have fueled a wave of studies into immunotherapy in breast cancer (BC). Compared with other BC subtypes, TNBC shows a better response to immunotherapy due to the higher level of tumor mutation burden and lymphocyte infiltration. Thereinto, immune checkpoint inhibitors (ICIs) achieved the first success of immunotherapy for TNBC and are widely utilized with conventional treatments in the neoadjuvant/adjuvant and advanced stages. However, a large number of TNBC patients fail to demonstrate a good response to ICIs, and the acquired resistance to ICI-based therapies is clinically emerging, which is a major challenge for immunotherapy in TNBC. Here we review the latest advances in TNBC immune microenvironment, immunotherapy, and immunotherapeutic resistance and discuss the challenges and potential approaches to improve the clinical benefit of immunotherapy against TNBC.
format	article
author	Xupeng Bai Jie Ni Julia Beretov Peter Graham Yong Li
author_facet	Xupeng Bai Jie Ni Julia Beretov Peter Graham Yong Li
author_sort	Xupeng Bai
title	Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
title_short	Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
title_full	Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
title_fullStr	Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
title_full_unstemmed	Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
title_sort	immunotherapy for triple-negative breast cancer: a molecular insight into the microenvironment, treatment, and resistance
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/b70b5e3637074d7693e3d1e8c38ef8fc
work_keys_str_mv	AT xupengbai immunotherapyfortriplenegativebreastcanceramolecularinsightintothemicroenvironmenttreatmentandresistance AT jieni immunotherapyfortriplenegativebreastcanceramolecularinsightintothemicroenvironmenttreatmentandresistance AT juliaberetov immunotherapyfortriplenegativebreastcanceramolecularinsightintothemicroenvironmenttreatmentandresistance AT petergraham immunotherapyfortriplenegativebreastcanceramolecularinsightintothemicroenvironmenttreatmentandresistance AT yongli immunotherapyfortriplenegativebreastcanceramolecularinsightintothemicroenvironmenttreatmentandresistance
_version_	1718405566521409536

Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance

Ejemplares similares